Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

>> Preview...
In the News

Greg Scott joined Foley's Eye on China web conference.
>> More information…

Simcere Given OK by SFDA for Flu Drug Relenza

publication date: Feb 11, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Simcere Pharma (先声药业) reported it has received SFDA approval to manufacture and market Relenza (zanamivir), the flu treatment developed by GlaxoSmithKline (NYSE: GSK). Relenza, an inhaled neuraminidase inhibitor, is one of only two approved drugs for treating H1N1 flu. Simcere holds an exclusive license for Relenza in China. More details...

Stock Symbol: (NYSE: SCR)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events
Munich, Germany
November 14, 2010
Suzhou, China
November 17-18, 2010
>>More details...
 
Partner Events

BioPharm America™ 2010
Boston, MA, USA
September 15–17, 2010
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners